Onyinye Onyeka Akunne1, Brian Godman2,3, Aduragbenro Deborah Adedapo1, Ilse Truter4, Joseph Fadare5. 1. Department of Pharmacology & Therapeutics, University of Ibadan, Nigeria. 2. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden. 3. Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK. 4. Drug Utilization Research Unit (DURU), Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth 6031, South Africa. 5. Department of Pharmacology, Ekiti State University, Ado-Ekiti, Nigeria.
Abstract
BACKGROUND: Statins reduce cardiovascular risk, especially in patients with hypertension due to their concomitant blood pressure reducing effects. Prescribing generic statins minimizes cost and improves access. AIMS: Ascertain current prescribing of statins in Nigeria and potential savings from the increased use of generic statins. METHODS: Prospective study involving hypertensive patients attending University College Hospital (Ibadan, Nigeria). RESULTS: In total, 228 hypertensive patients received statins. Atorvastatin was the most prescribed statin, followed by simvastatin, rosuvastatin and finally fluvastatin. Prescribed doses were less than one defined daily dose in the majority, with high use of originators. Average monthly potential savings from increased prescribing of generic statins was US$2635 for atorvastatin and US$10,578 for rosuvastatin. CONCLUSION: A shift toward increased prescribing generic statins is recommended to minimize costs.
BACKGROUND: Statins reduce cardiovascular risk, especially in patients with hypertension due to their concomitant blood pressure reducing effects. Prescribing generic statins minimizes cost and improves access. AIMS: Ascertain current prescribing of statins in Nigeria and potential savings from the increased use of generic statins. METHODS: Prospective study involving hypertensivepatients attending University College Hospital (Ibadan, Nigeria). RESULTS: In total, 228 hypertensivepatients received statins. Atorvastatin was the most prescribed statin, followed by simvastatin, rosuvastatin and finally fluvastatin. Prescribed doses were less than one defined daily dose in the majority, with high use of originators. Average monthly potential savings from increased prescribing of generic statins was US$2635 for atorvastatin and US$10,578 for rosuvastatin. CONCLUSION: A shift toward increased prescribing generic statins is recommended to minimize costs.
Authors: Brian Godman; Debashis Basu; Yogan Pillay; Julius C Mwita; Godfrey Mutashambara Rwegerera; Bene D Anand Paramadhas; Celda Tiroyakgosi; Patrick Mbah Okwen; Loveline Lum Niba; Justice Nonvignon; Israel Sefah; Margaret Oluka; Anastasia N Guantai; Dan Kibuule; Francis Kalemeera; Mwangana Mubita; Joseph Fadare; Olayinka O Ogunleye; Larry A Distiller; Enos M Rampamba; Jeffrey Wing; Debjani Mueller; Abubakr Alfadl; Adefolarin A Amu; Zinhle Matsebula; Aubrey Kalungia; Trust Zaranyika; Nyasha Masuka; Janney Wale; Ruaraidh Hill; Amanj Kurdi; Angela Timoney; Stephen Campbell; Johanna C Meyer Journal: Front Pharmacol Date: 2020-03-20 Impact factor: 5.810